1. Home
  2. ONCO

ONCO

Onconetix Inc.

Logo Onconetix Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Founded: 2018 Country:
United States
United States
Employees: N/A City: CINCINNATI
Market Cap: 2.8M IPO Year: 2022
Target Price: N/A AVG Volume (30 days): 3.8M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.19 EPS Growth: N/A
52 Week Low/High: $0.14 - $1.58 Next Earning Date: 05-10-2024
Revenue: $58,465 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: